Introduction
============

At the interface with the bloodstream, neurovascular units (NVUs) are structural and functional multicellular modules consisting of neurons, perivascular astrocytes, microglia, pericytes, extracellular matrix and the endothelial cells of the brain microcirculation. They provide a coordinated neurovascular coupling and maintain a highly selective blood-brain barrier (BBB) ([@B1]). The dynamic multicellular crosstalk within the NVUs in physiological and pathological conditions could reveal novel cell-targeted therapeutic strategies with impact on the BBB, cerebral homeostasis and brain functions ([@B6]; [@B3]).

The endothelial cells of the BBB are interconnected by tight and adherens junctions and form a continuous layer. This layer selectively buffers the impact of fluctuations in blood composition on brain interstitial fluid, regulating the brain microenvironment and neuronal signaling ([@B2]). Various transcellular transport systems across the BBB have been described, as carrier mediated transport, receptor-mediated transport, ion transfer, efflux carriage, adsorptive-mediated passage, and fluid-phase endocytosis ([@B87]).

Apart from the classical modes of intercellular communication, such as ligand-receptor interactions, direct cell-cell contacts (e.g., gap junctions) or paracrine signaling ([@B39]), a significant experimental evidence has confirmed that several physiological and pathophysiological processes are controlled by the extracellular membrane vesicles, such as exosomes and microvesicles, secreted from various cellular sources into the body fluids and interconnecting cells without direct cell-to-cell contact ([@B78]). This type of signaling occurs mainly through exosomes, which are nano-sized vesicles that easily transfer biological information from cell to cell. This is achieved by means of exosomal molecules that would usually not cross membrane barriers. This shows the capability of inducing functional changes in target cells and modulating local and systemic crosstalk ([@B46]). In the brain, exosomes are released from all types of cells ([@B34]) and are bidirectionally transported through the blood-brain communication interfaces, blood-brain and blood-cerebrospinal fluid barriers ([@B9]). These blood-brain interfaces are potential pathways for therapeutically administered exosomes.

Given their capacity to easily reach body compartments and connect origin cells with target cells, exosomes have a promising potential to be used in clinical applications. Indeed, exosomes have shown the capacity to serve both as biomarkers and novel therapeutic tools in the nervous system pathologies lacking efficient therapies, such as stroke ([@B11]). The cellular interactions within NVU might contribute to (i) the restoration of a well-organized cerebral microvasculature by providing trophic support and a stimulating brain microenvironment ([@B42]), and (ii) the remodeling of parenchymal tissue, including axonal sprouting, dendritic growth and synaptic reorganization ([@B41]). However, there is still more to explore about the diagnostic benefits and therapeutic roles of exosomes, their production, release, transport, uptake, signaling potential, change of their cargo proteins profile and miRNAs ([@B86]). Here, we review the roles of exosomes in mediating the intercellular crosstalk within the NVU and the therapeutic potential of exosomes derived from multipotent mesenchymal stem cells (MSCs) in stroke.

Exosomes' as a Biological Communication Tool
============================================

Exosomes are defined as 30--100 nm sized membrane vesicles derivatives of the endosomal compartment and correspond to the intraluminal vesicles of multivesicular bodies (MVBs) that upon fusion of the MVBs with the plasma membrane are released as exosomes into the extracellular environment ([@B50]), where they act as signaling organelles for intercellular communication. From the extracellular milieu, exosomes may contact target cells by (i) receptor-mediated adhesion to the cellular plasma membrane, followed by endocytic uptake and internalization, (ii) direct fusion of the exosome membrane with the target cell membrane and subsequent exosomal content release into the recipient cell ([@B10]).

Exosomes' vesicles are homogenous in shape, surrounded by a phospholipid membrane displaying membrane proteins, such as cell-specific receptors, and containing cell-type specific combinations of lipids, metabolites, coding and non-coding RNAs (miRNA, sRNA), single- and double stranded DNA, cytosolic and membrane proteins including enzymes, growth factors, receptors and cytokines ([@B75]; [@B50]). Exosomal lipids (e.g., phosphoglycerides, sphingomyelin, cholesterol, ceramide) are important for providing structural stability. Proteins of the exosomes are characteristic for their endosomal origin, and include membrane transport and fusion proteins (annexins, flotillin), proteins involved in cell targeting (tetraspanins, mostly CD9 and CD63) or other proteins correlated with their biogenesis from MVBs, as the tumor susceptibility gene 101 (TSG101) ([@B4]). Exosomes also contain heat-shock proteins (Hsp60, Hsp70, Hsp90), known for their neuroprotective potential. Also, they expose low levels of phosphatidylserine and cell-type-specific proteins. One of the most important function of the exosomes is targeting cellular pathways in the recipient cells through their RNAs and miRNAs cargo ([@B52]).

Novel research supports exosomes as a fundamental mechanism of communication in the nervous system, with roles in brain homeostasis and plasticity ([@B44]), acting as bidirectional cargo in brain-periphery communication and within the brain, in between neurons, glia, vascular and perivascular cells (Figure [1](#F1){ref-type="fig"}). Exosome secretion has been described from (i) depolarized/stimulated cortical neurons, mainly from the somato-dendritic compartments ([@B33]; [@B48]; [@B81]), (ii) oligodendrocytes ([@B34]), (iii) microglia ([@B66]), (iv) astrocytes when activated by oxidative and heat stress ([@B74]), (v) endothelial cells ([@B31]), and (vi) pericytes ([@B56]), known to generate MSCs in the perivascular area of the lesioned or inflamed vessels ([@B15]; [@B16]).
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The complex and versatile exosomal signaling was shown to impact the synaptic activity (e.g., neuronal origin exosomes exhibiting neurotransmitter receptors bind neurotransmitters within the synapse to stop signaling), *trans*-synaptic communication, synaptic plasticity, maintenance of myelination, angiogenesis, neurovascular integrity, but also on neuroregeneration and neuroprotection in response to disease conditions ([@B44]). For example, angiogenesis could be stimulated both by activation of signaling pathways PI3K, ERK1/2, Wnt4/ß-catenin or NF-kB and transfer of the transcription factors STAT3, STAT5, transfer of lipids like S1P, transfer of proteins including VEGF, FGF-2, PDGF, metalloproteases, but also by the transfer of micro-RNA-126, miR-214, miR-296, and miR-150 (for a review, see [@B76]). Likewise, after experimental stroke, treatment with exosomes isolated from miR-133b-overexpressing MSCs, significantly increased functional improvement and neurite remodeling/brain plasticity in the ischemic boundary area compared with control animals ([@B83]). Recently, it was also reported that miR-26a is a physiological regulator of mammalian axon regeneration by targeting glycogen synthase kinase 3β (GSK3β) in adult mouse sensory neurons *in vitro* and *in vivo* ([@B77]).

Exosomes can also propagate inflammation across the BBB and within the brain, as brain endothelial cells activated by systemic inflammation further activate the neighboring cells in the NVU via secreted exosomes ([@B9]; [@B44]). The pathogenic role of microglia-derived exosomes in the inflammatory response was demonstrated in a model of traumatic brain injury (TBI) i.e., *in vitro* activated microglia-derived exosomes induced neuroinflammation at the site of injection and around the lesion. Furthermore, circulating enriched exosomes or CD11b-isolated microglia from the TBI brain *ex vivo*, initiated neuroinflammation following intracortical injection in naïve animals ([@B80]; [@B47]). The pathogenic effects of microglia-derived exosomes could be mediated by pro-inflammatory mediators TNF-alpha, IL-1β and miR-155 ([@B47]).

Also, exosomes contribute to disease spreading by acting like Trojan horses for neurodegenerative agents (e.g., toxins, such as tetanus toxin, protein aggregates, such as phosphorylated Tau, amyloid Aβ or synuclein) ([@B12]; [@B44]). Through their non-coding RNA cargo and miRNA transfer, exosomes are involved in epigenetic regulation of neuro-glial communication within the nervous system, but also in brain-body epigenetic interconnection ([@B49]).

Neurovascular Unit Remodeling in Response to Stroke
===================================================

Following the failure of acute neuroprotection therapies, major efforts are currently made worldwide to promote neurological recovery and brain plasticity in the subacute and post-acute phases of stroke. For over more than two decades, therapeutic efforts in the stroke field have focused on the promotion of neuronal survival, which failed to succeed in clinical trials in humans until now ([@B71]; [@B37]). From failure to translate successful neuroprotection therapies from animal models to humans, it may be concluded that the stimulation of survival alone is without prospect, as long as no successful remodeling of brain tissue stimulated by a permissive microenvironment takes place. Indeed, studies done recently have shown that extensive remodeling occurs in the brain following an ischemic event ([@B43]; [@B41]). Currently, there is hope that stroke recovery might be promoted through pharmacological or cell-based therapies. Indeed, promising results from experimental studies have led to clinical trials, the results of which are currently awaited ([@B50]).

Remodeling of ischemic brain tissue involves interactions between neurons, glial and microvascular cells that create a microenvironment in which neurological recovery may ensue. Neurons and brain capillaries sprout. Neuronal outgrowth enables the formation of functional axons and synapses in the brain both over long \[e.g., along pyramidal tract ([@B5]; [@B68])\] and short (e.g., within motor cortex ([@B22]; [@B42]) distances, thus allowing for the restitution of neuronal networks that were damaged by the stroke event. The remodeling of ischemic brain tissue also includes responses of immature cells, namely of endothelial progenitor cells (EPC), neural progenitor cells (NPC), and inflammatory cells. New blood vessels are formed, and EPC and NPC are attracted to the stroke lesion. Glial cells contribute to the remodeling of the extracellular matrix, enabling neuronal plasticity.

In the process of brain remodeling, proliferating microvascular cells play a supportive role, enabling the migration of neural precursor cells and promoting the remodeling of neurons and glial cells via secretion of growth factors ([@B43]). This rearrangement of cell-cell interactions is followed by the recovery of the BBB, leading to the restoration of brain homeostasis ([@B42]).

The remodeling potential of the NVU serves as an important therapeutic target in stroke and other acute neurologic conditions. After stroke, damaged and inflamed endothelium release pro-inflammatory factors and extracellular vesicles (EVs) that pass through the leaky BBB and activate astrocytes and microglia to release pro-inflammatory cytokines (TNFα, IL1β) ([@B60]). Microglia also release the anti-inflammatory cytokine IL-10 that acts on reactive astrocytes to modify their cytokine secretion from a pro-inflammatory profile toward a pro-recovery one, represented mainly by TGFβ. During the post-stroke BBB repair and parenchymal remodeling process, NVU cells cooperate and release pro-recovery factors (e.g., IL-4, IL-10, TGFβ) that switch microglia into a pro-remodeling phenotype that release growth factors ([@B60]). Moreover, IL-10 acts on the endothelial and vascular cells to modulate vascular repair and remodeling, diminishes leukocyte--endothelial interactions, decreases expression and activation of cytokine receptors, promotes NO-induced vasodilatation and diminish ROS production and oxidative stress by inhibiting a NADPH oxidase subunit (Nox1) with impact on degenerative vascular remodeling ([@B24]; [@B36]). Overall, IL-10 secreted from the NVU cells, but also from MSCs and their exosomes ([@B59]), is a pro-survival factor for neurons and glial cells that diminishes the post-lesional inflammatory response and limits the secondary damage during the resolution phase ([@B57]).

Pericytes behavior in different phases of ischemic stroke were recently described ([@B85]). Briefly, during the stroke hyperacute phase, pericytes constriction causes capillary occlusion (no-reflow phenomenon). Then, during the acute phase, pericytes have a pro-inflammatory and immune-modulatory action, with consecutive increase in BBB permeability and brain edema. By protecting the endothelium on its abluminal side and through release of neurotrophins, pericytes stabilize the BBB and protect brain parenchyma. Further, during post-stroke recovery phase, pericytes have a neuroprotective activity, promoting angiogenesis, neurogenesis, and brain recovery. The complex multifaceted, multistage pericytes intervention in ischemic-reperfusion injury and repair processes, recommend them for new targeted therapeutic strategies ([@B14]).

Neurovascular Unit-Derived Exosomes in Response to Stroke
=========================================================

Pericytes are important players in post-stroke NVU remodeling. Thus, they were shown to become activated and gain multipotent stem cell phenotype after brain ischemia and express the neuroepithelial stem cell marker nestin, with a potential to differentiate into neural and vascular precursor lineages ([@B58]). Cooperation between endothelial cells and pericytes occurs both through paracrine interaction, but also through an exosomal bidirectional communication and is essential for preserving the microvascular functionality and stability. For example, endothelium or pericyte-derived hypoxic exosomes were shown to induce an angiogenic program ([@B32]; [@B56]). Secondary to local injury and perivascular inflammation, MSCs are released from their perivascular location and secrete bioactive molecules and exosomes with immunomodulatory and trophic effects, supporting the regenerative microenvironment needed for the post-injury recovery ([@B17]). A recent work even suggests that perivascular MSCs are adventitial cells, acting as precursors of pericytes and other stromal cells during tissue homeostasis ([@B25]). Not all pericytes can generate MSCs. It has been recently shown that from the various sub-population of existing pericytes, not all of them can act like stem cells, and some act like fibroblasts.

Neuronal exosomes are present at synaptic level, both within pre- and postsynaptic compartments, and transport synaptic receptors (e.g., AMPA receptors, GPCRs) ([@B45]) contributing to synaptic plasticity, both locally and within broader neuronal networks ([@B18]). The activity within glutamatergic synapses, which is increased in post-stroke excitotoxic conditions, stimulates neuronal release of exosomes that preferentially bind to adjacent neurons, impacting on interneuronal communication ([@B21]). The exosomes released secondary to neuronal depolarization are rich in miRNAs, potentially promoting synaptic plasticity by enabling the rapid translation of associated proteins ([@B38]).

The interactions between neurons, glial cells and microvascular cells are finely tuned. They involve mutual cell to cell communication via release of growth factors as well as physical cell-cell interactions across the extracellular matrix that is itself subjected to remodeling processes after stroke ([@B69]). Considering the complexity of these systems and considering both the structural and functional heterogeneities of brain structures and the heterogeneities of ischemic strokes with regard to their size, etiology, and localization ([@B41]), the development of neurorestorative therapies is a true challenge ([@B40]).

The Potential Use of Mesenchymal Stem Cells and Their Exosomes for Stroke Therapy
=================================================================================

Ischemic stroke is a leading cause of death and long-term disability in industrialized countries, with thrombolysis and interventional vascular recanalization being the only treatments available. Due to severe side effects and a narrow therapeutic time window, only a small proportion of stroke patients receive this therapy. Thus, additional therapeutic concepts are mandatory ([@B41]). Strategies that promote neuronal survival in the acute stroke phase have successfully been studied in experimental stroke models, but were not successful in clinical trials. Therefore, the research focus has recently shifted from the acute to post-acute stroke phase ([@B41]). After acknowledging that transplanted cells integrate poorly into existing neural networks and that they induce brain remodeling in a paracrine way by secreting a heterogeneous group of nanovesicles, these EVs have been identified as key players that mediate restorative effects of stem and progenitor cells in ischemic brain tissue. Neuroprotection as observed after EV infusion in experimental stroke models is related to stem cell application in stroke. As a matter of fact, stem cell-induced neurological recovery after stroke is not a consequence of cell regeneration but due to paracrine mechanisms of grafted cells, among which stem cell-derived EVs are key mediators ([@B26]).

Blood-brain barrier may block or diminish the access of therapeutic agents within the central nervous system and therefore many nervous system diseases lack an efficient treatment because of a deficient drug delivery vehicle. Considering this important issue, research is nowadays developing nanocarriers for brain targeted drug delivery and exploit the potential use of stem cells to secrete exosomes, as natural nanovesicles rich in biological active molecules. As lipid-bound nanoparticles, exosomes easily interconnect cells and cross selective-permeable membranes such as BBB, thus emerging as versatile tools for new therapeutic strategies (e.g., regenerative, immune-modulatory or anti-tumor therapies), either acting through their biochemically active constituents (e.g., proteins, lipids, genetic material), or serving as natural nonimmunogenic vehicles for drug delivery ([@B50]).

Non-exosomal Effects of Mesenchymal Stem Cells
----------------------------------------------

The human brain contains reservoirs of neural stem and precursor cells in the subventricular zone (SVZ) surrounding the lateral ventricles ([@B7]). Although cerebral ischemia triggers the activation of these cells and promotes their migration toward ischemic lesion sites, their siblings hardly survive and differentiate within the ischemic milieu ([@B27], [@B30]). To improve brain remodeling and plasticity, and to bypass limitations of endogenous neurogenesis following ischemic stroke, a variety of approaches started to focus on the transplantation of NPCs or somatic stem cell entities, such as MSCs ([@B64], [@B63], 2011). MSCs secretome comprises growth factors, cytokines, chemokines, extracellular matrix components, genetic material, but also EVs (exosomes and microvesicles), recommending them as versatile tools in clinical applications ([@B35]).

Mesenchymal stem cells, known as "sentinel and safe-guards of injury" ([@B16]), were shown to produce neurotrophic factors such as nerve growth factor, brain-derived neurotrophic factor, or glial-derived neurotrophic factor, explaining their therapeutic potential ([@B55]).

Initially, it was assumed that transplanted NPCs and MSCs home to affected sites and, upon expansion and differentiation, directly replace the lost brain cells to restore tissue functions. In this context, our lab has comprehensively characterized the therapeutic effects of SVZ-derived adult NPCs in a mouse model of ischemic stroke, i.e., transient proximal (i.e., intraluminal) middle cerebral artery occlusion (MCAO). We observed that systemic NPC delivery induces profound brain tissue remodeling, reflected by reduced secondary neurodegeneration, reduced neuroinflammation, reduced astrogliosis and reduced microglial activation, that was associated with functional neurological recovery ([@B7]; [@B27], [@B29],[@B30]). Remarkably, it turned out that systemic intravenous administration of adult NPCs was more effective than intracerebral transplantation. Indeed, systemic administration effectively resulted in the stabilization of BBB integrity. However, just 0.1--0.3% of intravenously transplanted NPCs were detected in the brain and most of them were in an undifferentiated state ([@B7]). These findings imply that NPCs act in a paracrine rather than a cellular mode.

Exosomal Effects of Mesenchymal Stem Cells
------------------------------------------

The exosomes' database ExoCarta^[1](#fn01){ref-type="fn"}^ reports more than 900 species of proteins associated with MSCs-derived exosomes, but recent data from proteomic analysis, identified more than 2000 proteins in MSC-exosome, many of them being involved in brain repair ([@B61]). These were shown to increase glial production of anti-inflammatory and immuno-regulatory mediators, TGFβ1 and IL-10 ([@B13]), with significant roles in NVUs' recovery and remodeling. Also, it was recently shown that IL-10 is one of the neuroprotective factors through which transplanted MSCs act after an ischemic stroke. Thus, MSCs overexpressing IL-10 improved neuronal survival in the ischemic hemisphere ([@B59]). Interestingly, MSCs-derived exosomes were shown to exhibit post-stroke changes in their miRNA profile, mostly in the miRNAs actively involved in the repair process by altering gene expression and promoting brain recovery ([@B53]).

Classically, paracrine effects were thought to be mediated by soluble molecules such as growth factors, cytokines, chemokines and hormones. More recent data, however, demonstrate that several physiological and pathophysiological processes are controlled by exosomes ([@B23]). In experimental stroke models, evidence was provided that exosomes exert neuroprotective, proangiogenic and neuronal plasticity-promoting functions ([@B84]). Thus, systemic administration of MSC-derived exosomes in a rat model of stroke improved functional recovery and enhanced neurite remodeling, neurogenesis, and angiogenesis ([@B84]). Furthermore, administration of combined xenogenic (from mini-pig) adipose-derived mesenchymal stem cell (ADMSC) and ADMSC-derived exosome therapy has been shown to reduce brain-infarct zone (BIZ) and enhance neurological recovery in rat after acute ischemic stroke ([@B19]). At molecular level the beneficial effects of MSC-derived exosomes could be mediated by the miR-17-92 cluster. Thus, rats subjected MCAO and treated with miR-17-92 cluster-enriched exosomes, performed significantly better than the control rats treated with MSC exosome alone ([@B82]). Similarly, administration of exosomes isolated from miR-133b-overexpressing MSCs lead to increased neural plasticity and improvement of functional recovery after stroke in rats ([@B83]).

Based on these observations, we performed a direct head-by-head comparison of the therapeutic effects of MSCs and their exosomes in a murine model of transient intraluminal MCAO, which predominantly affects the striatum and most lateral parts of the overlying cerebral cortex, showing that systemic MSCs and MSC-derived exosomes are equally effective in enhancing stroke-related motor and coordination recovery thereby confirming the beneficial effects of the exosome therapy reported by Chopp and colleagues who observed a significant reduction in neurological impairment that improved gradually over 4 weeks after systemic delivery of MSC-derived EVs (MSC-EVs) in a model of transient MCAO in rats ([@B84]). Both therapies promoted post-ischemic endogenous neurogenesis and angiogenesis and reversed the stroke-associated immunodepression ([@B28]).

Conclusion and Perspectives
===========================

Ischemic stroke is a leading cause of death and long-term disability for which no restorative therapy is available. After stroke, the NVU is compromised and has become a major target for restorative therapies in the central nervous system. Emerging research has revealed that the nano-sized exosomes could be used for the NVU remodeling after stroke, due to their ability to mediate cell-to-cell communication. Considering the side effects typically attributed to cell-based therapies, in particular, malignant transformation of the transplanted cells, MSC-derived exosomes are attractive candidates for stroke therapy, as emphasized by a recent position paper ([@B50]). Indeed, systemic administration of MSC-derived exosomes is effective in enhancing stroke-related motor and coordination recovery in experimental stroke models, fueling the hope for clinical studies. Nevertheless, for clinical applications we need further studies to shed light on (i) mechanisms of the interaction between exosomes and target cells, (ii) circulation kinetics and biodistribution; (iii) biogenesis mechanism; (iv) potential side effects. For example, tumor-secreted exosomes may act as mediators in cancer metastasis by maintenance and enhancement of tumor microenvironment ([@B70]; [@B20]; [@B51]). Likewise, several studies have reported high levels of cholesteryl ester (CE), triacylglycerol (TAG) and cardiolipin in exosomal preparations fueling concerns about increasing the risk of stroke instead of having a beneficial effect ([@B54]; [@B79]; [@B73]; [@B67]; [@B72]; [@B65]).

Furthermore, considering that ischemic stroke mainly affects elderly patients, experimental data in aged rodents are urgently required before a clinical proof-of-concept study in human patients should be envisaged ([@B64], [@B63], 2018; [@B8]).
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